Because ARF6 activation significantly reduced tumor cell death after MAPKi (Fig. 4c–f), we asked whether inhibition of ARF6 could sensitize melanoma to clinically acquired or innate MAPKi resistance. The gene discussed is ARF6; the disease is neoplasm.